SCHEMBL4707889

SCHEMBL4707889

COc1cc(NC(=O)CBr)c(C(=O)c2cccc(C#N)c2)cc1O[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 3/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPK1 P28482 2/20 0.38
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 2/20 0.37
TP53 P04637 1/20 0.37
GSK3B P49841 1/20 0.37
GAA P10253 2/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
AKR1C4 P17516 1/20 0.36
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
MAPT P10636 1/20 0.35
AHR P35869 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4708654 1.00 VNN1 (0.38) VNN1KDM4EMAPK1HSD17B10ALDH1A1
SCHEMBL4707995 0.83 VNN1 (0.41) VNN1KDM4EHSD17B10CYP3A4MAPT
SCHEMBL4708513 0.83 VNN1 (0.41) VNN1KDM4EHSD17B10CYP3A4MAPT
SCHEMBL4709546 0.67 KDM4E (0.48) VNN1KDM4EALDH1A1GSK3BDRD2
SCHEMBL9575546 0.67 NPC1 (0.47) VNN1TP53GSK3BGAASMN1; SMN2
SCHEMBL25412907 0.66 KDM4E (0.36) KDM4EMAPK1HSD17B10ALDH1A1TP53
SCHEMBL31022799 0.65 HTT (0.43) KDM4EMAPK1HSD17B10ALDH1A1CYP3A4
SCHEMBL25410686 0.65 KDM4E (0.34) KDM4EMAPK1HSD17B10ALDH1A1TP53
SCHEMBL23094059 0.64 ABCC9 (0.51) VNN1KDM4EALDH1A1GSK3BMAPT
SCHEMBL5062220 0.64 KDM4E (0.43) KDM4EMAPK1HSD17B10ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1556055-B1 CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE AND THEIR USE IN THERAPY VIA PHARMACEUTICALS INC (US) 2008-10-29 EP disclosed
US-20060128695-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses NEURO3D (FR) 2006-06-15 US disclosed
EP-1556055-A2 USE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS HAVING A BENZODIAZEPINE STRUCTURE IN THERAPY NEURO3D (FR) 2005-07-27 EP disclosed
WO-2004041258-A2 CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES NEURO3D (FR) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128695-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses PDE7A, PDE4A, PDE4B VNN1 456/4885KDM4E 2333/4885MAPK1 2096/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.